In Apr 2021, BMY announced that this study hit its OS primary endpoint for both the Opdivo/chemo and Opdivo/Yervoy arms, compared to chemo alone (#msg-163050617), but no details were available until now.
The dataset is complex and you need a scorecard to understand all of it; fortunately, Evaluate Vantage has provided one:
Note: Opdivo/chemo is already FDA-approved in a different kind of metastatic GI cancer, based on the CHECKMATE-649 (rather than -648) study (#msg-163247972); and Opdivo monotherapy is already FDA-approved in adjuvant esophageal cancer, based on the CHECKMATE-577 study (#msg-163936079).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”